Benefits of boswellia, betaine, and myo-inositol in the treatment of breast fibroadenomas

The fibroadenoma is the most common benign breast neoplasm in young women between the ages of 15 and 25. From a histological and clinical point of view, this nodular formation arises from an altered response of the stromal and epithelial tissues to hormonal stimuli. In the vast majority of cases, the fibroadenoma does not require immediate medical or surgical intervention, unless significant painful symptoms (mastalgia) or cytological and architectural atypia are found on biopsy examination, which would increase its risk profile.

Traditional pharmacological options for controlling benign lesions or managing breast density have historically relied on treatments with anti-estrogenic action. Although effective in the short term, these therapies have significant clinical limitations: they are frequently hampered by side effects that lead to treatment discontinuation and show a high rate of recurrence upon discontinuation.

In this context lies the nutraceutical research aimed at molecules capable of integrally modulating inflammatory, metabolic, oxidative, and endocrine pathways. A fundamental contribution was made by researchers from the Department of Surgical Sciences of the University of Rome La Sapienza, led by Prof. Vittorio Pasta, through an important randomized clinical study.

The Biological Rationale: Molecular Synergy

The formulation combination examined harnesses the complementary properties of three key active ingredients:

• Boswellia serrata: Acts as a powerful natural anti-inflammatory agent thanks to the selective inhibition of the 5-lipoxygenase (5-LOX) enzyme, reducing the production of leukotrienes and the parenchymal inflammatory microenvironment.
• Myo-inositol: Plays a crucial role in cell signaling transduction and the regulation of insulin sensitivity, indirectly influencing the gonadotropic axis and reducing epithelial overstimulation related to estrogens and growth factors.
• Betaine (Trimethylglycine): Acts as a methyl group donor and cellular osmolyte, participating in homocysteine metabolism and reducing oxidative stress and abnormal tissue proliferation.

The researchers' hypothesis was that this synergy could not only reduce inflammation and cell proliferation, but also promote the structural regression of the nodule and the concurrent reduction of breast density — the elevation of which represents a known independent risk factor for the development of breast cancer.

Study Design and Clinical Results

The clinical trial (Pasta V. et al., Eur Rev Med Pharmacol Sci 2016) was conducted as a randomized, double-blind, placebo-controlled, parallel-group study on 64 patients aged 30 or younger (mean age 22.5 ± 7.5 years). The diagnosis of fibroadenoma was formulated through a triple-verification diagnostic protocol: clinical examination, breast ultrasound, and tissue biopsy using a cutting needle (CNB - Core Needle Biopsy).

The participants were divided into two groups treated for a period of 6 months with the administration of 2 capsules twice a day:

• Experimental Group (n = 36): Treated with the complete formulation (Eumastos), containing Boswellia serrata (50 mg of extract standardized to 30% beta-boswellic acid), betaine (175 mg), myo-inositol (200 mg), N-acetylcysteine (NAC) and B vitamins.
• Placebo Group (n = 28): Treated solely with N-acetylcysteine and B vitamins.

At the end of the 6 months of monitoring, the data showed a statistically and clinically significant difference between the two treatment arms:

Clinical Perspectives and Tolerability

A major finding of the study concerns the safety profile: no significant adverse effects were reported throughout the trial in the group treated with the combination of Boswellia, betaine, and myo-inositol.

The concurrent reduction in parenchymal density and fibroadenoma size confirms the validity of this integrated approach, offering gynecologists and breast surgeons an effective therapeutic option for the conservative management of benign lesions in young women. Further clinical trials involving larger population samples will enable these findings to be further consolidated and long-term maintenance protocols to be established.

Bibliographic References

1. Pasta V, Dinicola S, Giuliani A, Harrath AH, Alwasel SH, Tartaglia F, et al. A randomized trial of boswellia in association with betaine and myo-inositol in the management of breast fibroadenomas. Eur Rev Med Pharmacol Sci 2016 May; 20(9): 1860-1865.
2. Pasta V, Dinicola S, Custureri B, et al. Boswellia, betaine and myo-inositol in the treatment of mammographic breast density: a randomized, double-blind, placebo-controlled trial. Eur Rev Med Pharmacol Sci 2015 Nov; 19(22): 4419-4426.
3. Bizzarri M, Fuso A, Dinicola S, Cucina A, Bevilacqua A. Pharmacological activities of myo-inositol in the treatment of metabolic and endocrine dysfunctions. Expert Opin Drug Metab Toxicol 2016; 12(10): 1181-1196.
4. Ammon HP. Boswellic acids and their role in physiological and pathological inflammatory responses. Adv Exp Med Biol 2016; 929: 291-327.